Sector News

Hovione appoints Frédéric Kahn as VP Marketing and Sales

September 28, 2017
Life sciences

Hovione announced today the appointment of Mr. Frédéric Kahn as Vice President Marketing and Sales, as of 1st September, 2017.

Mr. Kahn was most recently with Lonza and brings more than 30 years of experience in sales and marketing, finance and business management with a proven track-record of building and developing successful organizations. Based in Lisbon, Portugal, Mr. Kahn will report to Mr. Guy Villax, Hovione’s Chief Executive Officer.

“We are delighted to welcome Mr. Kahn to Hovione. He is an excellent addition to our management team as his diverse cross-functional experience in marketing and sales, business management and industry knowledge will help drive Hovione’s forthcoming growth. Mr. Kahn will be responsible for leading Hovione’s global Marketing and Sales activities, driving demand for products and services, as we continue our growth and focus on delivering the highest level of service to our customers”, said Mr. Guy Villax.

“I am very proud to join Hovione, a company so highly respected in the industry for its ability to develop and produce innovative, high-quality products and I look forward to work with Hovione multi-functional teams of experts to develop the best solutions for our customers”, said Mr. Frédéric Kahn.

Mr. Kahn started his career in 1985 as Division Controller of Rhone-Poulenc Organic Chemicals (later known as Rhodia Pharmaceutical Ingredients, later Aventis) where he held several senior executive positions in sales and business management in the US, Europe and Singapore. Mr. Kahn`s responsibilities focused on development, production and formulation of anesthetics and analgesics’ APIs. In 2003 Mr. Kahn joined NextPharma as Executive Vice President Sales and Marketing to generate sustainable growth by setting up a dedicated Key Account Management strategy and organization. After five successful years, Mr. Kahn joined the German Pharmaceutical Packaging and Medical Devices leader Gerresheimer based in Duesseldorf where sales to strategic accounts grew at double digit rate. His last role before joining Hovione was in Lonza as Head of Global Key Account Management.

Passionate about sales and strategic account management, Mr. Kahn is a member of SAMA Association, holds a Bachelor of Sciences in Economics from the College of New Jersey and an MBA from ISG,Institut de Controle de Gestion, Paris.

Source: Hovione

comments closed

Related News

January 22, 2023

Sun Pharma to buy Concert Pharmaceuticals for $576m

Life sciences

Sun Pharmaceutical Industries has signed a definitive agreement to buy all outstanding shares of Concert Pharmaceuticals in a deal valued at $576m. Under the deal, the company will buy all shares of Concert common stock through a tender offer for $8.00 per share in cash upfront payment.

January 22, 2023

Novo Nordisk diabetes pill wins FDA approval for first-line use

Life sciences

The Food and Drug Administration on Thursday approved Novo Nordisk’s diabetes pill Rybelsus as an initial treatment to lower blood sugar levels, a label expansion that will allow it to compete more directly with other oral drugs from Merck & Co. and Eli Lilly.

January 22, 2023

Bayer feeling more heat from activist investors, this time from Bluebell

Life sciences

Since making an ill-advised $63 billion buy of Monsanto in 2018, Bayer has faced heaps of pressure from investors that have called for the company to oust its leadership and to restructure. Now comes new pressure from a familiar source. Bluebell Capital Partners has bought an undisclosed stake in the company and is agitating for a breakup, sources told Reuters.

How can we help you?

We're easy to reach